The Prognostic Significance of Fibrosis Detection in Cardiomyopathy

Royal Brompton & Harefield NHS Foundation Trust

Status: Enrolling

Conditions: Coronary Artery Disease; Cardiomyopathy

Study type: Observational

Funder types: Other

Identifiers

NCT00930735

09/0904

Details and patient eligibility

About

The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure

Clinical significance Correlation with biomarkers and genetic markers

Full description

Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion using pharmacological stress imaging (contraindications to include comorbidities that do not permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic stenosis)

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• presence of an ischaemic or non-ischaemic cardiomyopathic process
• no contraindication to contrast enhanced CMR
• GFR >30

Exclusion criteria

• ESRF
• Contraindication to CM R

Trial design

3,000 participants in 1 patient group

Myocardial fibrosis, outcomes

Description:

Groups with none and variable amounts of myocardial fibrosis